A
Alcista
Alcista · 25%AUPH
$12.60
Precio del escenario
$16.860
-0.457 (-2.71%)Al cierre
Loading chart…
- Máximo
- 17.310
- Apertura
- 17.270
- Precio medio ponderado por volumen
- 16.99
- Volumen
- 649.24K
- Capitalización
- 803.77M
- Mínimo
- 16.810
- Importe
- 11.03M
- EV/EBITDA, TTM
- 9.28
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. It has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct clinical and regulatory activities to support the LUPKYNIS development program. The Company is also developing aritinercept (AUR200), a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases. It sells LUPKYNIS to specialty pharmacies and a specialty distributor in the United States and sells LUPKYNIS inventory to its collaboration partner, Otsuka Pharmaceutical Co., Ltd. (Otsuka), for the European and Japanese market. The Company sells encapsulated voclosporin to its collaboration partner, Otsuka, which Otsuka then sells to customers in its territories.
Análisis de IA of Aurinia Pharmaceuticals Inc. (AUPH)
ComprarAurinia Pharmaceuticals Inc is a good buy right now due to its current price of $16.86, a strong gross margin of 92.12%, and a forward P/E ratio of 11.83, suggesting solid valuation. The recent acquisition of shares by the CEO for $12.5 million indicates confidence in the company's future. However, the main risk is the potential volatility indicated by an implied volatility of 54.66%.
Recomendaciones de analistas (5)
-2.14% Potencial de caída
Comprar
5 Comprar
0 Mantener
0 Vender
Actual: 16.86
Mínimo
13.00
Promedio
16.50
Máximo
21.00
Leerink
Market Perform
$16
2025-12-03
Leerink
2025-12-03
Precio objetivo
$16
Market Perform
Jefferies
Comprar
$21
2025-11-07
Jefferies
2025-11-07
Precio objetivo
$21
Comprar
RBC Capital
Sector Perform
$15
2025-11-04
RBC Capital
2025-11-04
Precio objetivo
$15
Sector Perform
Cantor Fitzgerald
Comprar
$10
2024-09-16
Cantor Fitzgerald
2024-09-16
Precio objetivo
$10
Comprar
Cantor Fitzgerald
Comprar
$10
2024-09-09
Cantor Fitzgerald
2024-09-09
Precio objetivo
$10
Comprar
Métricas de valoración
El PER previsto actual de Aurinia Pharmaceuticals Inc. (AUPH) es 11.83, frente a su media de 5 años de 9.01.
Escenarios de precio de Alphio AI para AUPH
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con AUPH en cartera
Cronología de eventos
Noticias
7.008-19stocktwitsAurinia Settles Patent Dispute with Teva, Delaying Generic Launch
9.508-06seekingalphaAurinia Pharmaceuticals Q2 Earnings Beat Expectations
5.006-07NASDAQ.COMAurinia Pharmaceuticals CEO Acquires Shares Worth $12.5 Million
5.006-07FoolAurinia CEO Kevin Tang Acquires 814,606 Shares
5.006-03NASDAQ.COMDirector Paul J. Fribourg Acquires 273,500 Shares of IFF
Preguntas frecuentes sobre AUPH, respondidas por Alphio AI
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. It has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct clinical and regulatory activities to support the LUPKYNIS development program. The Company is also developing aritinercept (AUR200), a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases. It sells LUPKYNIS to specialty pharmacies and a specialty distributor in the United States and sells LUPKYNIS inventory to its collaboration partner, Otsuka Pharmaceutical Co., Ltd. (Otsuka), for the European and Japanese market. The Company sells encapsulated voclosporin to its collaboration partner, Otsuka, which Otsuka then sells to customers in its territories. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Aurinia Pharmaceuticals Inc is a good buy right now due to its current price of $16.86, a strong gross margin of 92.12%, and a forward P/E ratio of 11.83, suggesting solid valuation. The recent acquisition of shares by the CEO for $12.5 million indicates confidence in the company's future. However, the main risk is the potential volatility indicated by an implied volatility of 54.66%.
5 analysts cover AUPH: 5 rate it Buy, 0 Hold and 0 Sell. The average price target is 16.50.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.